ArticleJournal of neuro-oncology2006
Predicting which children are at risk for ependymoma relapse.
Article in Journal of neuro-oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.Journal of neuro-oncology · 2016Trial
- Intracranial ependymomas: molecular insights and translation to treatment.Brain pathology (Zurich, Switzerland) · 2020Review
- Article
- p16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.Pediatric blood & cancer · 2017Article
- Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.Acta neuropathologica · 2014Article
- Tumor prognostic factors and the challenge of developing predictive factors.Current oncology reports · 2013Article
- Tumor profiling: development of prognostic and predictive factors to guide brain tumor treatment.Current oncology reports · 2011Review
- Article
- Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.Neuro-oncology · 2008Review
- Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma.British journal of cancer · 2008Article
- Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma.Neoplasia (New York, N.Y.) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ependymomas account for 6-12% of all pediatric intracranial tumors. Despite complete resection and radiation, about 50% of patients relapse and have subsequent dismal prognoses. As no clinical findings reliably forecast tumor recurrence, we sought to determine if gene expression profiling could be used to distinguish patients at high risk for relapse at initial diagnosis, and thereby make them candidates for innovative treatments at an early stage. We extracted RNA from 13 ependymoma specimens: 7 from patients who experienced tumor recurrence, and 6 from patients who have not recurred. RNA was applied to Affymetrix HG-U133 plus 2.0 microarray chips, and microarrays were analyzed with GeneSpring 7.0 and Prediction Analysis of Microarrays (PAM) software. The 3-gene subset of PLEK (pleckstrin), NF-kappaB2 (nuclear factor kappa beta-2), and LOC374491 (TPTE and PTEN homologous inositol phosphatase pseudogene) was identified as the minimal subset capable of accurately distinguishing tumors according to recurrence. In summary, gene expression profiling may be valuable, perhaps in combination with clinical findings identified in some studies, for identifying children at high risk for ependymoma relapse.
Indexed as
Identifiers
16575538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.